#lly

Eli Lilly $LLY moved higher after reports that the company plans nearly $4B of vaccine acquisitions. The planned deals clear the Tier-1 M&A threshold and extend Lilly’s GLP-1 cash flow into infectious-disease assets.

$LLY rose more than 10% after Eli Lilly posted Q1 revenue of $19.8 billion, adjusted EPS of $8.55, and lifted its 2026 sales outlook by $2 billion.